So, guys, Derek, moreplacemoredates.com.

Today we're going to be talking about this new topical finasteride study that just came out,

a phase three randomized controlled clinical trial.

It was evaluating the efficacy and safety of topical finasteride and comparing it to oral.

So obviously, you know, on paper, topical finastriide sounds great. It's like, well,

let's get localized inhibition of five alpha reductase. If we can just inhibit five alpha

alpha reduction of testosterone to DHC in the scalp as opposed to systemically, well, then we can

prevent hair loss just on your scalp and then leave the rest of your body intact

to not inhibit physiologic functions and androgen dependent things in the body.

Like you're not inhibit your libido in any aspect, not inhibit gyno prevention.

You know, like a lot of shit that is driven through androgen, androgenicity in the body,

otherwise is going to be, you know, dulled to some extent when you are

inhibiting systemic DHD. Now, a lot of that is just from like a, honestly, like a secondary

sexual characteristic vector as opposed to like an actual muscle tissue vector, because as we know,

DHT is essentially inactivated in muscle tissue to a degree where it has

no significant impact on hypertrophic response or strength and we see that even in trials where they

literally wipe out dhc entirely with dasteroide and graded dose response to testosterone administration

we find no difference, essentially, in strength

or muscle growth metrics whatsoever when you have DHD inhibited versus not.

And that's entirely or almost entirely with dutasteride versus finasteride.

So muscle growth is not really a issue when it comes to finasteride.

However, obviously obviously you know like

...